Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill ‘Superbugs’ as Part of Bear’s Den Innovation Program

Hackensack Meridian Health has invested in the clinical-stage biotechnology company Adaptive Phage Therapeutics (APT), as part of the health network’s successful innovation program, the Bear’s Den.

APT is taking aim at the toughest multi-drug resistant “superbugs” using precision-targeted, genomically-screened, and highly purified viruses known as bacteriophages, or “phages.”

Read More